DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Raltitrexed
Raltitrexed
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib In
Clinical Efficacy of Irinotecan Plus Raltitrexed
Diarrhea Increased with Targeted Cancer Agents
(12) Patent Application Publication (10) Pub. No.: US 2013/0211215 A1 Heglund Et Al
Clinical Outcomes of Doxorubicin-Eluting Callispheres
BC Cancer Benefit Drug List September 2021
Comparison of E Cacy and Safety of Second-Line
The Value of Pemetrexed for the Treatment of Malignant Pleural Mesothelioma: a Comprehensive Review CHRISTEL C.L.M
Pharmaceuticals As Environmental Contaminants
Wear the Battle Gear That Protects Against 52 Chemotherapy Drugs!
DRUG NAME: Raltitrexed
Valproate–Doxorubicin: Promising Therapy for Progressing Mesothelioma
Carboplatin in Combination with Raltitrexed
Recommendations for the Adjustment of Dosing in Elderly Cancer Patients with Renal Insufficiency
CYTOTOXIC and NON-CYTOTOXIC HAZARDOUS MEDICATIONS
For Health Professionals Who Care for Cancer Patients
2548.Full-Text.Pdf
CEA Fluctuation During a Single Fluorouracil-Based Chemotherapy Cycle for Metastatic Colorectal Cancer
Top View
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010
Biweekly Oxaliplatin, Raltitrexed, 5-Fluorouracil and Folinic Acid Combination Chemotherapy During Preoperative Radiation Therap
Electronic Supplementary Material (ESI) for Lab on a Chip. This Journal Is © the Royal Society of Chemistry 2020
2012 NIOSH List of Antineoplastic and Other Hazardous Drugs
Induces Thymineless Death with Topoisomerase I-DNA Complexes
Activity and Toxicity of Oxaliplatin Plus Raltitrexed in 5-Fluorouracil Refractory Metastatic Colorectal Adeno-Carcinoma
Pre-Operative Radiochemotherapy with Raltitrexed for Resectable Locally-Advanced Rectal Cancer: a Phase II Study*
Formulation of Folate-Modified Raltitrexed-Loaded Nanoparticles
Hair Loss and Chemotherapy
MANUAL for Medical Facilities
Cytochrome P450 1B1 Gene Polymorphisms As Predictors of Anticancer Drug Activity: Studies with in Vitro Models
Management of Extravasation of a Systemic Anti-Cancer Therapy Including Cytotoxic Agents
EMA/PDCO Summary Report on the Review of the List of Granted Class Waivers
SAHA Overcomes 5-FU Resistance in IFIT2-Depleted Oral Squamous Cell Carcinoma Cells
Schedule-Dependent Synergism and Antagonism Between Methotrexate
Oncology Agents Not Listed in Seer Book 8
Selective Preservation of Pemetrexed
Phase I Trial and Pharmacokinetic Study of Raltitrexed in Children with Recurrent Or Refractory Leukemia: a Pediatric Oncology Group Study